clinical trial · NCT04042402
Long Term Extension Study in Patients With Primary Hyperoxaluria
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company·phase3·active not recruiting·n = 75
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney DiseasesUrologic DiseasesGenetic DiseasePrimary Hyperoxaluria Type 3 (PH3)DCR-PHXC
brief summary
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.
started
Jul 9, 2019
primary completion
Apr 1, 2030
completion
Apr 1, 2030
last updated
May 30, 2025
official title
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol